from a 4 degree spacing to a 2 degree spacing. In this study we evaluated the effect of control point interpolation on the dose distribution in the patient and on plan delivery at the linac. Materials and Methods: VMAT plans to treat stage III lung tumours were created for 8 patients. All plans were optimized with a 4 degree control point spacing. When the plan was clinically acceptable the control point spacing was interpolated to 2 degrees. For both plans we compared the coverage of the 95% isodose of the PTV minus lung tissue,the PTV max dose, the mean lung dose, the lung V20 and the maximum dose in the myelum. Both plans (interpolated and original) were send to the record and verify system (MosaiQ) and irradiated on a cubic solid water phantom (30x30x20 cm) using an Elekta Synergy linac. The dose in the isocenter was verified using a pinpoint ionisation chamber. In a consecutive session, the dose in the coronal isocentric plane was measured using the Octavius detector 729. Monitor units per control point were scaled in Pinnacle using a script to compensate for the angular dependence of the sensitivity of the detector. For both types of plans we compared the results of the measurements and the duration of the treatment. To compare array measurements and planned dose we used a gamma criterion of 2mm/2%. The dosecriterion was taken relative to the isocentric dose in the phantom. Doses below 30% of the maximum measured dose were excluded from the gamma calculation. Results: Effects of control point interpolation on the PTV-lung coverage, mean lung dose and lung V20 were negligible. PTV max dose was on average 0,8% higher in the interpolated plans, with a maximum of 2,2%. The mean increase in the maximum dose in the myelum was 0,1 Gy with a maximum of 0,4 Gy. The accuracy of the pinpoint measurements for the original and interpolated plans were not statistically significant: average difference between planned isocentric dose and measured dose was -0,3% (SD 1,6%) for 4 degree control point spacing and -1,3% (SD 1,1%) for 2 degree control point spacing. For the 4 degrees per control point plans we measured an average gamma pass rate of 82,4% with the best plan having a pass rate of 90,0% and the worst plan a 73,6% pass rate. For the interpolated plans the average pass rate was 82,2% while the best and worst plan had a pass rate of 89,0% and 70,8% respectively. Finally we also measured the delivery time of the original and interpolated plans and observed that interpolated plans always took longer to deliver with a mean delivery time of 103,5 seconds compared to 94,5 seconds for a 4 degree spacing plan. Conclusions: We observed that interpolation of control point spacing from 4 to 2 degrees does not increase the agreement of measurement and dose calculation. In addition, the effect on the DVH parameters is negligible while both the time needed for planning and delivery increases. We therefore refrain from using control point interpolation in our clinic.
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The effect of intravenous contrast agent on dose calculation in computed tomography based radiotherapy planning C. Constantinescu Purpose/Objective: To retrospectively evaluate the influence of intravenous contrast agent on dose calculation in CT-based threeDimensional-Conformal-Radiation-Therapy (3D-CRT) for pelvis and head-and-neck cancer patients, using two different dose calculation algorithms, Dose-Volume Histograms (DVHs) and 3D gamma index analysis.
Materials and Methods:
We randomly selected 10 pelvis and 10 headand-neck patients, for which two sets of CT images were acquired in the same position, before and after intravenous contrast agent injection. CT-based planning was performed in Eclipse treatment planning system, version 10, using Analytical Anisotropic Algorithm (AAA), with a calculation grid of 2.5 mm, and applying heterogeneity correction. A radiation oncologist contoured the target volumes and organs at risk (OARs) on the CT images without contrast, after registering them with CT images with contrast. A treatment plan was performed on the CT scan without contrast, and then copied to the CT scan with contrast using the same planning data when recalculating the dose. Re-plans were similarly performed on Monaco treatment planning system, version 3.0, using a Monte Carlo (MC) dose calculation algorithm, with a calculation grid of 2.5 mm and 1% variance.
DVHs from these plans were analyzed. The statistical data analysis was performed using the Wilcoxon matched pairs test; a p-value of < 0.05 was considered significant. A 3D gamma index analysis was performed, and the differences in dose distribution between two plans evaluated, for various combinations of distance-to-agreement (DTA) of 1 mm, 2 mm, and 3 mm and dose difference criteria of 2%, 3%, 4%, and 5%. Results: DVH analysis showed no significant difference between with and without contrast CT treatment plans. 
Conclusions:
The presence of intravenous contrast agent does not significantly affect the dose calculation in CT-based 3D-CRT planning of pelvis and head-and-neck. Purpose/Objective: The dosimetric aspects of radiotherapy treatment plan quality are evaluated with isodoses and dose volume histogram (DVH) values. Usually, the reporting consists in some particular values for target volumes (TV) and organs at risk (OAR). However, due to the complexity of the IMRT dose distributions, given a patient and treatment goals, several operators produce their own optimal plan depending on their experience and their tradeoffs between TV and OAR DVH endpoints. The aim of this study was (1) to evaluate the operator variability in our institution and (2) to improve the relevancy of the DVH endpoints. The study focused on Tomotherapy planning for head and neck cases. Materials and Methods: Ten patients with bilateral lymphatic node irradiation were selected from our database. Prescribed doses for planning target volumes PTV(tumor) and lymphatic nodes PTV(nodes) were 70Gy and 56Gy in 35 fractions respectively. For each patient, seven physicists of our department produced their own plan based on the same set of contours and the same treatment goals. For plan validation, DVH endpoints were related to the following organs: GTV (D98%), PTV(tumor) (D98%, D2%), PTV(nodes) D(98%), spinal cord (D2%), parotid glands (Dmean, V45Gy, V30Gy), larynx (V50Gy), oral cavity(V50Gy). The inter-operator variability was studied by comparing the DVH values. Three groups of values were evaluated (i) PTVs, (ii) principal OARs for which the respect of endpoints is mandatory and (iii) secondary OARs for which the respect of endpoints improves the patient quality of life. Results: Physicists had an experience with Tomotherapy planning software ranging from 1 to 5 years. 70 plans were generated and were evaluated by a single physician. For all patients, all plans were clinically acceptable despite some discrepancies. For group (i), the main difference concerned D98% for PTV(tumor) and PTV(nodes) that were lower for two planners. For group (ii), the D2% to the spinal cord never exceeded 38Gy. Large differences were observed but they were considered minor by the physician. For group (iii), experience and tradeoffs of the planners yielded different dosimetric results, especially in the larynx and in the ipsilateral parotid gland. This organ sparing can lead to an slight undercoverage of the PTV(tumor). Whatever the group, differences were particularly observed for the first patients studied, but were reduced during the study. Conclusions: This work showed inter-operator variability in Tomotherapy planning for head and neck cases. However, all plans were acceptable by the physician. This comparison allowed to better define the priority of the endpoints to evaluate the quality of a plan and to narrow the variability over the study. Purpose/Objective: Volumetric-modulated arc therapy (VMAT) is a relatively new treatment modality, in which gantry rotation and speed, dose-rate and multileaf collimator (MLC) leaves motion vary simultaneously. The aim of the study was to compare conventional intensity modulated radiation therapy (IMRT) with VMAT plans for prostate cancers. Materials and Methods: Ten randomly selected patients with prostate cancer were included for the present study. Contours for each pts were drawn using our clinical protocol. For each patient, three plans were generated for treatment modalities using a 80 leaves MLC with the leaves of 10 mm (MLCi2 Elekta Synergy). All IMRT and VMAT plans were calculated for 6MV photons. IMRT plan were generated using Oncentra Master Plan (v 3.3), whereas VMAT plans were performed with Monaco (v 3.2). The dose prescription was 76 Gy in 38 fractions to the target volume with respect the dose volume criteria for the organ at risk (OAR) complied with QUANTEC recommendation. Dosevolume parameters of the plans were evaluated according to Rapport ICRU N o 81. Results: All techniques: IMRT as well as VMAT result in treatment plans which comply with our current applied clinical protocol. From the DVH data, target coverage achieved similar results for IMRT and VMAT (table1): V95% -99,3±0,7% and 99,2±0,7% for IMRT and VMAT, respectively. The average dose were 102,5±3,2% for IMRT and 102,4±3,3% for VMAT. For OAR all planning objectives were largely met. VMAT plans were superior for rectum in all dose-volume constraints (p<0.05). Similar results were achieved in dose-volume constraints for bladder. VMAT leads to the average reduction of about 6 Gy for the mean dose for rectum and of about 11 Gy for mean dose for bladder comparing to IMRT. There were no statistical differences between IMRT and VMAT in mean and dose-volume parameters for femurs. The average MU were 452±.81,7, and 510.9±.50,6for IMRT and VMAT, respectively. Conclusions: VMAT achieved similar target coverage to IMRT plans for prostate cancer pts. It provided a better OAR sparing due to reduction of high-dose-receiving area of healthy tissue. Further studies are indicated to evaluated the VMAT impact on quality of life of prostate cancer pts during and after the therapy. 
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